Quality of life during active treatment for pediatric acute lymphoblastic leukemia

Area of Science:

• Pediatric Oncology
• Health Outcomes Research
• Quality of Life Studies

Background:

• Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
• Understanding the quality of life (QoL) for children undergoing ALL treatment is crucial for supportive care.
• Previous research has highlighted the impact of cancer therapy on pediatric patients' well-being.

Purpose of the Study:

• To describe the quality of life (QoL) in children with acute lymphoblastic leukemia (ALL) undergoing active therapy.
• To identify predictors associated with diminished QoL in this pediatric population.
• To examine how QoL varies across different phases of ALL treatment.

Main Methods:

• A multi-institutional, cross-sectional study involving 206 children with ALL in first remission, at least 2 months post-diagnosis.
• Parent-reported QoL data collected using the PedsQL 4.0 Generic Core Scales and the PedsQL 3.0 Acute Cancer Module.
• Statistical analysis to compare QoL scores with population norms and identify predictive factors.

Main Results:

• Children with ALL had significantly lower overall, physical, and psychosocial QoL summary scores compared to healthy norms (1-2 standard deviations lower).
• In high-risk ALL, female gender and older age were associated with worse QoL.
• In standard-risk ALL, lower household income and unmarried parents predicted poorer QoL.
• QoL scores remained relatively consistent across different phases of ALL therapy.

Conclusions:

• Children undergoing active ALL therapy exhibit a reduced quality of life compared to their healthy counterparts.
• Predictors of lower QoL differ based on ALL risk stratification, involving demographic and socioeconomic factors.
• QoL during ALL treatment appears stable across therapy phases, but further longitudinal research is recommended to track individual patient trajectories.